Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.
Adding daratumumab to lenalidomide maintenance therapy after transplant in patients with multiple myeloma triples the minimal residual disease –negative conversion rate to 50.5% vs 18.8% with lenalidomide alone. The combination therapy reduces progression risk by 47% and achieves estimated 30-month progression-free survival rates of 82.7% vs 66.4% for lenalidomide alone.
Treatment protocol included 10 mg lenalidomide daily through day 28 of each 28-day cycle, with a potential increase to 15 mg after 3 cycles, while the daratumumab group also received 1800 mg subcutaneous injections weekly during cycles 1-2, biweekly during cycles 3-6, and monthly thereafter.
Myeloma Plasma Cell Myeloma Biologic Therapy Biologics Immunomodulator Lenalidomide Transplantation Transplant Healthcare And Medical Technology Health And Medical Tech Health And Med Tech Health And Medical Technology Healthcare Technology Medical Technology COVID-19 2019 Novel Coronavirus 2019-Ncov Wuhan Coronavirus Human Coronavirus HKU1 Human Coronavirus OC43
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SF Supervisor Proposes Mass Arrests, 'Drug Jails' for Downtown Drug CrisisSan Francisco Supervisor Matt Dorsey calls for 'mass arrests' of drug users and dealers, aiming for at least 100 daily arrests, and proposes establishing 'drug jails' with medical and clinical interventions. Critics argue this approach is misguided and instead advocates for expanded behavioral health services.
Read more »
Lymphopenia Linked to Poorer Survival in Multiple Myeloma PatientsA new study analyzing VA hospital patient data reveals that lymphopenia, characterized by a low absolute lymphocyte count, is a significant predictor of poorer overall survival in multiple myeloma patients. The study found that over half of patients diagnosed with MM exhibited lymphopenia at diagnosis, and those with severely low lymphocyte counts had a significantly shorter median survival compared to those with normal counts. Even with standard induction therapy, lymphopenia remained associated with inferior outcomes, underscoring the importance of further research into this potentially impactful clinical marker.
Read more »
Multiple Myeloma: A Silent Threat Disproportionately Affecting Black CommunitiesThis article explores the challenges of multiple myeloma diagnosis, particularly its impact on Black and brown populations. It highlights the importance of early detection, the role of community outreach programs, and the need for further research to understand the contributing factors to this health disparity.
Read more »
Man Shrinks By Three Inches After Rare Cancer But Thanks UK Team For Extending His LifePeter Wingrave, 77, from Crewkerne, was diagnosed with myeloma, an incurable blood cancer, and his vertebrae were being crushed. He was rushed in for urgent treatment at Yeovil Hospital and has since received fortnightly blood infusions and medication at home. While his cancer is slowly showing signs of creeping back, his health is stable thanks to the care he has received. The cancer teams at Somerset NHS Foundation Trust have now been given a Myeloma UK Clinical Service Excellence Programme (CSEP) Award for the quality of care they provide to people with myeloma.
Read more »
Alone but Connected: New Study Finds Media Access Enhances Solitude BenefitsA recent study reveals that total solitude isn't the most restorative form of alone time. Participants preferred being physically alone but connected through media like phones or books. Experts suggest choosing the type of alone time that best suits your individual needs.
Read more »
2025 Shopping Trends: Economic Concerns Shape Consumer Priorities, AI Enhances Tailored ExperiencesThe latest First Insight research reveals that heightened recession fears influence spending habits, with AI playing a crucial role.
Read more »